NPPA revises ceiling prices of 45 scheduled drugs, retail prices of 11 other products
|
Our Bureau, Mumbai
November 17 , 2016
|
|
The national drug pricing regulator National Pharmaceutical Pricing
Authority (NPPA) has fixed/revised ceiling prices of 45 scheduled
formulations of Schedule-I under Drugs (Price Control) Amendment Order,
2016 and Retail Price of 11 formulations under DPCO, 2013 as per
notification dated 10.11.2016.
Name of the 45 scheduled
formulations for which ceiling prices have been revised are pralidoxime
chloride (2 - PAM) injection, efavirenz tablet, imatinib capsule, folic
acid capsule, benzoyl peroxide cream, clomiphene capsule, acetazolamide
capsule, salbutamol capsule, paracetamol oral liquid, pheniramine
injection, naloxone injection, lorazepam injection, phenytoin injection,
ceftazidime powder for injection, artesunate + (sulphadoxine+
pyrimethamine) tablet, metoclopramide oral liquid, streptokinase
injection, povidone iodine solution, betamethasone cream, tropicamide
eye drop, cetrimide solution, mannitol injection, ranitidine injection,
dicyclomine injection, ciprofloxacin ointment, gentamicin drops,
pilocarpine drops, timolol drops, atropine drops, homatropine drops,
hydrocortisone injection, rifampicin tablet, fluconazole capsule,
efavirenz capsule, ritonavir capsule, paracetamol suppository,
paracetamol suppository, paracetamol oral liquid and
carboxymethylcellulose drops.
Name of the 11 scheduled
formulations for which retail prices have been revised are teneligliptin
+ metformin HCl tablet (Tenlimac M 1000), teneligliptin + metformin HCl
(SR)tablet, teneligliptin + metformin HCl (ER) tablet, diclofenac
sodium + paracetamol tablet, r -H u erythropoietin injection and
voglibose + metformin HCl (SR) tablet.
Retail price is
applicable only to the individual manufacturers/marketeers i.e. who have
applied for the same by submitting Form-I for price fixation/revision
as stipulated under DPCO, 2013 and subject to fulfillment of all the
applicable statutory requirements as laid down by the government under
relevant statutes/rules, including manufacturing license permission from
the Competent Authority i.e. the Central/State Licensing Authority, as
may be applicable, by the concerned manufacturers/marketing companies.
The
concerned manufacturers of these formulations shall furnish quarterly
return to the NPPA, in respect of production/import and sale of product
in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.
Manufacturers in case intending to discontinue above said formulations,
shall furnish information to the NPPA, in respect of discontinuation of
the production and/or import of above said formulation in Form-IV of
Schedule-II of the DPCO, 2013 at least six months prior to the intended
date of discontinuation.
In case the retail price of any of the
formulations is not complied with, as per instant price notification and
notes specified, then the concerned manufacturer/marketing company
shall be liable to deposit the overcharged amount along with the
interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
Consequent to the issue of
retail price of the formulations as specified in this notification, the
price order(s) if any, issued for concerned manufacturer/marketeer prior
to said date of notification, stand(s) superseded.
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|